Keno Gutierrez

Keno Gutierrez is a General Partner at BGV (BioGeneration Ventures) since September 2021 and serves as Chairman of the Board at FundaMental Pharma, which focuses on small inhibitors for neurodegenerative diseases. Keno is also a board member of several companies, including Brenig Therapeutics, Fibrocor Therapeutics, and Tessellate BIO, contributing to innovative therapies in fibrotic diseases and autoimmune control. Previous roles include Managing Director and Vice President at M Ventures, where Keno was responsible for biotechnology investments, and various board observer positions at companies like Riffyn and DNA Script, enhancing advancements in life sciences and technology. Keno holds an MBA from INSEAD, a Ph.D. from University College London, and a B.Sc (Hons) from the National Polytechnic Institute.